New Nucleic Acid Diagnostic Tests in Viral Hepatitis

ABSTRACT

The development of nucleic acid assays is of critical clinical importance for the diagnosis of viral hepatitis and the management of antiviral therapy. For both chronic hepatitis B and C, sensitive and quantitative assays are required for the monitoring of viral load. Better assays are being developed and their role in the management of antiviral treatment has been clearly demonstrated. Genotyping assays are critical for the decision of treatment strategies in hepatitis C, although in hepatitis B this issue is more debated. The detection of viral genome mutations for the diagnosis of hepatitis B virus resistance is critical with the use of nucleoside analogs. This may also prove useful for anti-hepatitis C virus therapy with the rapid development of specific inhibitors that may select for drug-resistant mutants.

KEYWORDS

Hepatitis B - hepatitis C - viral load - viral genome - mutations - genotypes - antiviral therapy

REFERENCES

• 1 Seeger C, Mason W S. Hepatitis B virus biology.  Microbiol Mol Biol Rev. 2000;  64 51-68
• 2 Locarnini S, Hatzakis A, Heathcote J et al.. Management of antiviral resistance in patients with chronic hepatitis B.  Antivir Ther. 2004;  9 679-693
• 3 Weiss J, Wu H, Farrenkopf B et al.. Real time TaqMan PCR detection and quantitation of HBV genotypes A-G with the use of an internal quantitation standard.  J Clin Virol. 2004;  30 86-93
• 4 Ronsin C, Pillet A, Bali C, Denoyel G A. Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay.  J Clin Microbiol. 2006;  44 1390-1399
• 5 Lai C L, Leung N, Teo E K et al.. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.  Gastroenterology. 2005;  129 528-536
• 6 Minuk G Y, Sun D F, Uhanova J et al.. Occult hepatitis B virus infection in a North American community-based population.  J Hepatol. 2005;  42 480-485
• 7 Miller R H, Robinson W S. Hepatitis B virus DNA in nuclear and cytoplasmic fractions of infected human liver.  Virology. 1984;  137 390-399
• 8 Yokosuka O, Omata M, Imazeki F, Okuda K, Summers J. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA.  Hepatology. 1985;  5 728-734
• 9 Fourel I, Cullen J M, Saputelli J et al.. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.  J Virol. 1994;  68 8321-8330
• 10 Mason W S, Cullen J, Moraleda G et al.. Lamivudine therapy of WHV-infected woodchucks.  Virology. 1998;  245 18-32
• 11 Dandri M, Burda M R, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.  Hepatology. 2000;  32 139-146
• 12 Kock J, Schlicht H G. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity.  J Virol. 1993;  67 4867-4874
• 13 Addison W R, Wong W W, Fischer K P, Tyrrell D L. A quantitative competitive PCR assay for the covalently closed circular form of the duck hepatitis B virus.  Antiviral Res. 2000;  48 27-37
• 14 He M L, Wu J, Chen Y, Lin M C, Lau G K, Kung H F. A new and sensitive method for the quantification of HBV cccDNA by real-time PCR.  Biochem Biophys Res Commun. 2002;  295 1102-1107
• 15 Kock J, Theilmann L, Galle P, Schlicht H. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus.  Hepatology. 1996;  23 405-413
• 16 Mason A L, Xu L, Guo L, Kuhns M, Perillo R P. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen.  Hepatology. 1998;  27 1736-1742
• 17 Werle-Lapostolle B, Bowden S, Locarnini S et al.. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.  Gastroenterology. 2004;  126 1750-1758
• 18 Wong D K, Yuen M F, Yuan H et al.. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients.  Hepatology. 2004;  40 727-737
• 19 Sung J J, Wong M L, Bowden S et al.. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.  Gastroenterology. 2005;  128 1890-1897
• 20 Wursthorn K, Lutgehetmann M, Dandri M et al.. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.  Hepatology. 2006;  44 675-684
• 21 Janssen H L, van Zonneveld M, Senturk H et al.. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.  Lancet. 2005;  365 123-129
• 22 Schildgen O, Sirma H, Funk A et al.. Variant of hepatitis B virus with primary resistance to adefovir.  N Engl J Med. 2006;  354 1807-1812
• 23 Lok A S, Zoulim F, Locarnini S et al.. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.  J Clin Microbiol. 2002;  40 3729-3734
• 24 Grandjacques C, Pradat P, Stuyver L et al.. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity.  J Hepatol. 2000;  33 430-439
• 25 Nafa S, Ahmed S, Tavan D et al.. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.  Hepatology. 2000;  32 1078-1088
• 26 Wilson J W, Bean P, Robins T, Graziano F, Persing D H. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay.  J Clin Microbiol. 2000;  38 3022-3028
• 27 Tran N, Berne R, Chann R et al.. European multicenter evaluation of a high density DNA probe arrays for the detection of hepatitis B resistance mutations and identification of genotype.  J Clin Microbiol. 2006;  44 2792-2800
• 28 Pang A, Yuen M F, Yuan H J, Lai C L, Kwong Y L. Real-time quantification of hepatitis B virus core-promoter and pre-core mutants during hepatitis E antigen seroconversion.  J Hepatol. 2004;  40 1008-1017
• 29 Zhang M, Gong Y, Osiowy C, Minuk G Y. Rapid detection of hepatitis B virus mutations using real-time PCR and melting curve analysis.  Hepatology. 2002;  36 723-728
• 30 Whalley S A, Brown D, Teo C G, Dusheiko G M, Saunders N A. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler.  J Clin Microbiol. 2001;  39 1456-1459
• 31 Pichoud C, Seignères B, Wang Z, Trepo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.  Hepatology. 1999;  29 230-237
• 32 Melegari M, Scaglioni P P, Wands J R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.  Hepatology. 1998;  27 628-633
• 33 Allen M I, Deslauriers M, Andrews C W et al.. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine.  Hepatology. 1998;  27 1670-1677
• 34 Zoulim F. In vitro models for studying hepatitis B virus drug resistance.  Semin Liver Dis. 2006;  26 171-180
• 35 Yang H, Westland C, Xiong S, Delaney W E. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector.  Antiviral Res. 2004;  61 27-36
• 36 Durantel D, Carrouee-Durantel S, Werle-Lapostolle B et al.. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.  Hepatology. 2004;  40 855-864
• 37 Durantel D, Brunelle M N, Gros E et al.. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing.  J Clin Virol. 2005;  34(suppl 1) S34-S43
• 38 Zoulim F. Antiviral therapy of chronic hepatitis B.  Antiviral Res. 2006 Apr 25;  , (Epub ahead of print)
• 39 Werle B, Cinquin K, Marcellin P et al.. Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.  J Viral Hepat. 2004;  11 74-83
• 40 Lai C, Gane E, Liaw Y-F et al.. Telbivudine versus lamivudine for chronic hepatitis B: first year results from the international phase III globe trial.  Hepatology. 2005;  42(suppl 1) 748A
• 41 Hadziyannis S, Tassopoulos N, Chang T et al.. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy.  Hepatology. 2005;  42(suppl 1) 745A
• 42 Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.  J Hepatol. 2005;  42 302-308
• 43 Halfon P, Bourliere M, Penaranda G, Khiri H, Ouzan D. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection.  J Clin Microbiol. 2006;  44 2507-2511
• 44 Chevaliez S, Pawlotsky J M. Use of virologic assays in the diagnosis and management of hepatitis C virus infection.  Clin Liver Dis. 2005;  9 371-382 , v.
• 45 Comanor L, Elkin C, Leung K et al.. Successful HCV genotyping of previously failed and low viral load specimens using an HCV RNA qualitative assay based on transcription-mediated amplification in conjunction with the line probe assay.  J Clin Virol. 2003;  28 14-26
• 46 Pawlotsky J M. Therapy of hepatitis C: from empiricism to eradication.  Hepatology. 2006;  43(suppl 1) S207-S220
• 47 McHutchison J G, Bartenschlager R, Patel K, Pawlotsky J M. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.  J Hepatol. 2006;  44 411-421
• 48 Yi M, Tong X, Skelton A et al.. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor: reduced RNA replication fitness and partial rescue by second-site mutations.  J Biol Chem. 2006;  281 8205-8215
• 49 Perni R B, Almquist S J, Byrn R A et al.. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.  Antimicrob Agents Chemother. 2006;  50 899-909
• 50 Le Pogam S, Kang H, Harris S F et al.. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.  J Virol. 2006;  80 6146-6154
• 51 Kim Y J, Kim S O, Chung H J et al.. Population genotyping of hepatitis C virus by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of short DNA fragments.  Clin Chem. 2005;  51 1123-1131